Bristol-myers Squibb Compnay

Dupont Pharmaceuticals Company

Robert M Knabb

Jinglan Zhou

Mimi Lifen Quan

William Henry Miller

John Matthew Fevig

Jon J Hangeland

Robert A Galemmo, Jr

Patricia C Weber

Matthew M Abelman

Joseph Cacciola

Cailan Wang

Dietmar A Seiffert

Pancras C Wong

Gregory James Pacofsky

Eugene Cruz Amparo

The present invention provides compounds of Formula (I): or a stereoisomer or pharmaceutically acceptable salt form thereof, wherein the variables A, B, L, L, X, X, X, X, R, R, R, R, Rand Rare as defined herein. The compounds of Formula (I) are useful as selective inhibitors of serine protease enzymes of the coagulation cascade and/or contact activation system; for example thrombin, factor Xa, factor XIa, factor IXa, factor VIIa and/or plasma kallikrein. In particular, it relates to compounds that are selective factor XIa inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

Tetrahydroquinoline derivatives useful as serine protease inhibitors

The present application describes methods of using a combination of 1-(3'-aminobenzisoxazol-5&#x2032;-yl)-3-trifluoromethyl-5-[[4-[(2&#x2032;-dimethylaminomethyl)imidazol-1&#x2032;-yl]-2-fluorophenyl]aminocarbonyl]pyrazole-hydrochloric acid salt, a factor Xa inhibitor, and Clopidogrel as anticoagulant agents for treatment of thromboembolic disorders and pharmaceutical compositions containing the same.

Combination of a factor Xa inhibitor and clopidogrel

This invention relates to electrophilic dipeptide analogs conjugated to an N,N-disubstituted .alpha.-amino acid as inhibitors of trypsin-like serine protease enzymes.

Electrophilic peptide analogs as inhibitors of trypsin-like enzymes

Growing community of inventors

Avondale, PA, United States of America

Robert M Knabb